Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial).
White blood cell (WBC) count and temperature are 2 global measures of inflammation that are systematically gathered and easily identifiable in a clinical setting, unlike many other markers of inflammation being investigated in patients with coronary artery disease. The prognostic usefulness of the WBC count and temperature were evaluated in a large acute myocardial infarction trial, the Complement And ReDuction of INfarct size after Angioplasty or Lytics program. Baseline and serial measurements of WBC counts and temperature were correlated with infarct size and clinical outcome.
Patel
Manesh R
MR
Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.
Mahaffey
Kenneth W
KW
Armstrong
Paul W
PW
Weaver
W Douglas
WD
Tasissa
Gudaye
G
Hochman
Judith S
JS
Todaro
Thomas G
TG
Malloy
Kevin J
KJ
Rollins
Scott
S
Theroux
Pierre
P
Ruzyllo
Witold
W
Nicolau
Jose C
JC
Granger
Christopher B
CB
D017130:Angioplasty; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D019540:Area Under Curve; D001831:Body Temperature; D016009:Chi-Square Distribution; D003402:Creatine Kinase / Q000097:blood; D006801:Humans; D007958:Leukocyte Count; D016014:Linear Models; D009203:Myocardial Infarction / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D011237:Predictive Value of Tests; D011379:Prognosis; D057127:Single-Chain Antibodies; D016019:Survival Analysis; D015912:Thrombolytic Therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D057127:Single-Chain Antibodies; C402724:pexelizumab; D003402:Creatine Kinase